You searched for "interview"
High dose (2.5mg) bevacizumab for postradiation cystoid macular oedema
The authors present a retrospective, interventional case series investigating the efficacy of high dose (2.5mg/0.1ml) intravitreal bevacizumab in the treatment of persistent postradiation (Iodine-125 plaque brachytherapy for uveal melanoma) cystoid macular oedema (CME). Persistent CME was defined as increased or...
Efficacy and safety of intravitreal aflibercept injection in wet age-related macular degeneration
This is a sub-group study of double masked review of patients randomised to different dosages and treatment frequency compared between aflibercept and ranibizumab treatment. This is to evaluate the efficacy and safety of intravitreal aflibercept (IVT-AFL) in Japanese patients with...100% Ophthalmology Programme Insights
We spoke to some of the Eye News family about their upcoming presentations at 100% Opthalmology, 24–26 February 2024, ExCeL London, UK.Happy hour
Welcome Eye News Aug/Sep 2023, your bi-monthly tonic for a much-needed happy hour. In the current climate of challenge across all fronts, there’s no better time to reach out for the professional equivalent of a cheery cup in the company...Act now: Professor Serge Resnikoff on making myopia a public health priority
Over the past decade, myopia has shifted from a common childhood inconvenience to what global health leaders now call a “public health emergency in slow motion” [1]. According to Professor Serge Resnikoff, former Head of Eye Health at the World...
Post hoc analysis of the CANTREAT randomised trial
CANTREAT, a Canadian multicentre two-year randomised trial compares treat and extend treatment (T&E) relative to the monthly administration of Ranibizumab in nAMD. Two-hundred and eighty-five treatment-naïve patients with nAMD were randomised to receive either a once-monthly dosing or T&E regimen...On reflection
Welcome one and all to our festive Eye News Dec/Jan 2024. The arrow of time has flown through 2023, landing us at the year’s end, but not before Santa brings you this special delivery. Aside from the partying and generally...Clinical trial investigates ‘Light Touch’ approach to wet AMD treatment
A clinical trial led by NIHR Moorfields Clinical Research Facility will explore a new ‘light-touch’ treatment approach for patients with neovascular age-related macular degeneration (wet AMD) that could result in fewer injections and reduced number of clinic visits. Funded by...The fragile p-value
Abdus Samad Ansari explores the limitation of the p-value and the application of the fragility index in clinical trials. Clinical trials and tribulations? The restoration of vision or more purely the gift of sight is an aspect of care that...What's trending Feb/Mar 2020
#gbhockey #samward #sight Great Britain Hockey player Sam Ward, described as one of the “deadliest attackers in world hockey” [1], sustained a sight-threatening injury after being struck in the face by a ball during the Olympic qualifying match against Malaysia...Money is a problem, but the problem is bigger than money
The argument surrounding doctors’ pay remains an ongoing battle. At the time of writing, Foundation Year 1 doctors have voted in favour of industrial action due to the lack of substantive employment or regular locum work at the end of...
